Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
- Maastricht University (UM)
- CNRS
- Delft University of Technology (TU Delft)
- ETH Zürich
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- Luxembourg Institute of Science and Technology (LIST)
- NTNU Norwegian University of Science and Technology
- Technical University of Munich
- University of East Anglia
- Leibniz Institute for Natural Product Research and Infection Biology
- Luxembourg Institute of Science and Technology
- Newcastle University
- Queensland University of Technology
- SciLifeLab
- Stony Brook University
- THE UNIVERSITY OF HONG KONG
- The Norwegian School of Sport Sciences
- University of Birmingham
- University of Cambridge;
- University of Florida
- University of Foggia
- University of Mainz
- Vrije Universiteit Brussel
- Vrije Universiteit Brussel (VUB)
- 14 more »
- « less
-
Field
-
29.04.2026, Academic staff To strengthen our research group Metabolic Function & Biosignals / Section II, the Leibniz Institute for Food Systems Biology at the Technical University of Munich
-
20 Jun 2026 Job Information Organisation/Company Vrije Universiteit Brussel (VUB) Research Field Architecture » Other Engineering » Civil engineering Geography » Economic geography History
-
Drivers and Mechanisms of Carcinogenesis; 2. Lipid Signaling and Metabolism in Cancer; 3. Imaging, Biomarker Discovery and Engineering Sciences. Overarching themes across programs include Population
-
into the world of lipid research with the European doctoral network LipidBRIGHT to uncover how lipid signaling and metabolism drive disease—and innovate future therapies. PhD Position – Lipids and Cardiovascular
-
in the live organism to study e.g. immune responses or cancer development. Moreover, using molecular sensors we also aim to read out cellular functionality in vivo e.g. metabolic reprogramming in
-
developing innovative siRNA‑based therapies. Our research focuses on areas with high unmet medical need, including cardiovascular, metabolic, liver, and kidney diseases. We have access to a strong and